Haider, Stefan P.
Mahajan, Amit
Zeevi, Tal
Baumeister, Philipp
Reichel, Christoph
Sharaf, Kariem
Forghani, Reza
Kucukkaya, Ahmet S.
Kann, Benjamin H.
Judson, Benjamin L.
Prasad, Manju L.
Burtness, Barbara
Payabvash, Seyedmehdi
Article History
Received: 19 January 2020
Accepted: 24 April 2020
First Online: 12 May 2020
Compliance with ethical standards
:
: SPH has nothing to disclose. AM has nothing to disclose. TZ has nothing to disclose. PB has nothing to disclose. CR has nothing to disclose. KS has nothing to disclose. RF has acted as speaker and consultant for GE Healthcare and has a research agreement (beta tester) and support from GE Healthcare. RF is also a founder and stockholder of 4intelligent Inc., and a clinical research scholar (chercheur-boursier clinician) supported by the Fonds de recherche en santé du Québec (FRQS). ASK has nothing to disclose. BHK has nothing to disclose. BLJ has nothing to disclose. MLP has nothing to disclose. BB has nothing to disclose. SP has nothing to disclose.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the corresponding institutional research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all participants in prospective trials. The Yale University ethics committee waived consent for retrospective analysis of patients’ information under IRB protocol #2000024295 (“Imaging biomarkers for tumor classifications in brain and head/neck tumors using radiomics and machine-learning algorithms”).